Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N1177
- Development stage
- Preclinical
- Lead developer
- NanoScan Imaging
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
N1177 is an investigational, radio-opaque contrast agent developed by NanoScan Imaging LLC. It is an emulsified suspension composed of crystalline iodinated particles dispersed with a surfactant. Designed for use with computed tomography (CT) and CT angiography (CTA), N1177 is intended to visualize blood vessels, organs, and heart chambers, with a particular focus on detecting macrophage-rich atherosclerotic plaques. Its mechanism involves accumulating in macrophage cells, which are key components of vulnerable plaques, thereby enabling their detection. Unlike traditional contrast agents, N1177 is cleared through the liver, potentially reducing renal toxicity.
Beyond the preview
Go deeper on N1177.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N1177.